When Sitagliptin, a DPP-4 inhibitor, was added to insulin therapy in the treatment of poorly controlled patients with T2D, it was found that the combined group had a greater reduction in HbA1c level compared to the group with increased insulin dose. This evidence concerns the gene INS and type 2 diabetes mellitus.